Research uncovers why weight loss with Ozempic and Wegovy eventually plateaus
New research funded by the U.S. National Institutes of Health (NIH) has found that semaglutide, the active ingredient in the GLP-1 class of weight-loss drugs, sparks different responses in the brain cells responsible for appetite control. The findings, reported by Science Daily, offer a new perspective on why these drugs do not produce the same result in everyone.
Known by trade names such as Ozempic and Wegovy, semaglutide has been widely used in recent years to treat obesity and type 2 diabetes. The drugs work by mimicking GLP-1, a hormone that occurs naturally in the body and regulates appetite.
A common experience among users is that initial weight loss slows or stops after a time, reaching a 'plateau'. The research aims to illuminate the possible biological mechanisms behind this plateau.
According to the researchers, semaglutide does not act the same way across all appetite-control cells in the brain; different cell groups respond to the drug differently. This cellular diversity may explain differences in individual responses to treatment.
The study also points to a possible way to extend the drugs' effects. This can be read as an early clue that new treatment approaches might be developed in the future for patients who stall at a weight-loss plateau.
However, findings of this kind are basic research aimed at understanding the mechanism; they do not amount to a direct treatment recommendation. Turning laboratory-level discoveries into clinical practice is a long process requiring further studies and trials.
The spread of GLP-1 drugs has become the subject of broad debate over medical efficacy as well as access and cost. A better understanding of the mechanism of action matters for more targeted and effective use of the drugs.
Weight management is treated as a multi-faceted process that involves not only drugs but also nutrition, physical activity and underlying health conditions. Experts stress that drug treatment should be considered as part of this holistic approach.
The cell-level detail the research offers contributes to scientists' deeper understanding of appetite and metabolic regulation. Such fundamental knowledge lays the groundwork for future drug-development work.
In the end, the study provides important new data on individual differences in the effect of GLP-1 drugs and on the weight-loss plateau. (This is a health news report; it is not medical advice. Decisions about drug use and weight management should be discussed with health professionals.)